A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

NCT02555124 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-42847922, 5 mg
DRUG: JNJ-42847922, 20 mg
DRUG: JNJ-42847922, 40 mg
DRUG: Placebo

Sponsor

Janssen Pharmaceutical K.K.